CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
CorMedix beat Q3 earnings and revenue estimates, but DefenCath pricing pressure hurt sales. The excerpt also notes progress with Rezzayo and a planned Heron acquisition shaping the company’s 2027 outlook.
Why it matters — CRMD watchers may weigh the quarterly beat against sales pressure and the developments cited for its 2027 outlook.